Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases, has announced its upcoming participation in Leerink's Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for March 10, 2025, at 1:40 p.m. ET in Miami.
The event will be accessible through a live webcast, available on the company's website at www.designtx.com in the investors section. The presentation recording will remain archived and available for viewing for a minimum of 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DSGN declined 7.00%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at Leerink's Global Healthcare Conference 2025?
How can investors watch Design Therapeutics' (DSGN) presentation at the Leerink Conference?
How long will Design Therapeutics' (DSGN) Leerink Conference presentation be available for viewing?
What type of presentation will Design Therapeutics (DSGN) give at the Leerink Healthcare Conference?
